Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906200 | 1.00 | CHRM2 (0.32) | CHRM2CHRM1CHRM3IL1BP2RX7 | |
| SCHEMBL24758159 | 0.88 | IL1B (0.32) | IL1BP2RX7 | |
| SCHEMBL24906439 | 0.85 | IL1B (0.30) | IL1BP2RX7 | |
| SCHEMBL27417574 | 0.85 | IL1B (0.30) | IL1BP2RX7 | |
| SCHEMBL24906293 | 0.82 | SMN1; SMN2 (0.33) | IL1BP2RX7 | |
| SCHEMBL24758414 | 0.81 | HTR2A (0.31) | — | |
| SCHEMBL24906201 | 0.80 | HTR2C (0.37) | CHRM2CHRM1CHRM3IL1BP2RX7 | |
| SCHEMBL30107044 | 0.79 | SCN9A (0.32) | — | |
| SCHEMBL24906245 | 0.79 | FFAR4 (0.32) | — | |
| SCHEMBL24757826 | 0.78 | IL1B (0.31) | IL1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | CHRM2 2303/4885CHRM1 1719/4885CHRM3 1112/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | CHRM2 2303/4885CHRM1 1719/4885CHRM3 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.